PrecisionLife

Founded in 2014 and headquartered in Oxford, PrecisionLife is a private AI-driven precision medicine company targeting complex chronic diseases. Its core technology uses combinatorial analytics on genetic and multimodal patient data to identify novel disease mechanisms and patient subgroups, enabling the discovery of biomarkers for risk prediction and treatment response. The company operates a platform business model, partnering with biobanks, pharma, and healthcare systems to develop diagnostic tools (termed 'Mechanostics') and support therapeutic development, positioning itself as a key enabler in the shift towards personalized, preventative healthcare.

Proprietary AI-driven combinatorial analytics platform that analyzes multimodal patient data (primarily genetic) to identify non-linear interactions and causal disease mechanisms. It discovers 'Mechanostics' – biomarkers for patient stratification, target discovery, and diagnostic development.

PrecisionLife operates in the competitive AI-for-drug-discovery and computational biomarker space. Key competitors include companies like Recursion Pharmaceuticals, Insilico Medicine, and BenevolentAI, which also use AI for target discovery. Its specific focus on combinatorial genetics for patient stratification in chronic diseases differentiates it, but it competes for similar pharma partnerships and data access.